Absorption, pharmacokinetics and disposition of biodegradable nanoscale preparations

Current Drug Metabolism

Volumn 13, Issue 4, 2012, Pages 429-439

  Wang, Cheng ^a   Wang, Jing ^b   Chen, Tiezhu ^c   Luo, Zhiqiang ^b   Yang, Xuemei ^d   Pan, Xiongfei ^e   Lin, Yunfeng ^b   Qian, Zhiyong ^a,b   Cai, Xiaoxiao ^b  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

^c Sichuan Academy of Traditional Chinese Medicine Sciences   (China)

^d THIRD MILITARY MEDICAL UNIVERSITY   (China)

^e SICHUAN UNIVERSITY   (China)

Author keywords

Active targeting; Liposomes; Micelles; Nanoparticles; Passive targeting; PLGA; SLN

Indexed keywords

ABI 009; ANNAMYCIN; AURIMUNE; CAMPTOTHECIN; CISPLATIN; CLOZAPINE; DAUNORUBICIN; DOXORUBICIN; FERUMOXYTOL; FIRTECAN; INSULIN; IRINOTECAN; LIPOSOME; MBP 426; NANOPARTICLE; NC 4016; NC 6004; NK 911; OXALIPLATIN; PACLITAXEL; RAPAMYCIN; REXIN G; SLIT; SOLID LIPID NANOPARTICLE; THERMODOX; TRANSDRUG; UNCLASSIFIED DRUG;

ARTICLE; DRUG ABSORPTION; DRUG DISPOSITION; HUMAN; MICELLE; NANOPHARMACEUTICS; NANOTOXICOLOGY; NONHUMAN;

ABSORPTION; ANIMALS; DRUG CARRIERS; HUMANS; NANOSTRUCTURES; TISSUE DISTRIBUTION;

EID: 84860644212     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/138920012800166508     Document Type: Article

References (173)

1. Couvreur, P.; Vauthier, C. Nanotechnology: Intelligent design to treat complex disease. Pharm. Res., 2006, 23(7), 1417-1450. (Pubitemid 43993807)
2. Yuan, F.; Dellian, M.; Fukumura, D.; Leunig, M.; Berk, D.A.; Torchilin, V.P.; Jain, R.K. Vascular-Permeability in a Human Tumor Xenograft - Molecular-Size Dependence and Cutoff Size. Cancer Res., 1995, 55(17), 3752-3756.
3. Alving, C.R. Liposomes as carriers of antigens and adjuvants. J. Immunol. Methods, 1991, 140(1), 1-13.
4. Crommelin, D.J.A.; Storm, G. Liposomes: From the bench to the bed. J. Lipos.Res., 2003, 13(1), 33-36. (Pubitemid 36373342)
5. Crommelin, D.J.A.; Storm, G.; Jiskoot, W.; Stenekes, R.; Mastrobattista, E.; Hennink, W.E. Nanotechnological approaches for the delivery of macromolecules. J. Control. Release., 2003, 87(1-3), 81-88. (Pubitemid 36258388)
6. Buiting, A.M.J.; Rooijen, N.V.; Claassen, E. Liposomes as antigen carriers and adjuvants in vivo. Res. in Immuno., 1992, 143(5), 541- 548.
7. Malam, Y. ; Loizidou, M. Seifalian, A.M. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol. Sci., 2009, 30(11), 592-599.
8. Drummond, D.C.; Meyer, O.; Hong, K.L.; Kirpotin, D.B.; Papahadjopoulos, D.; Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol. Rev., 1999, 51(4), 691-743.
9. Kabanov, A.V. Self-assembled polymer colloids for drug and gene delivery. Abstr Pap Amer. Chem. Soc., 2001, 222, U319-U319.
10. Tirelli, N.; Lutolf, M.P.; Napoli, A.; Hubbell, Poly(ethylene glycol) block copolymers. Rev. Mol. Biotechnol., 2002, 90(1), 3-15. (Pubitemid 34179586)
11. Shuai, X.T.; Ai, H.; Nasongkla, N. Kim, S.; Gao, J.M. Micellar carriers based on block copolymers of poly(e-caprolactone) and poly(ethylene glycol) for doxorubicin delivery. J. Control. Release, 2004, 98(3), 415-426. (Pubitemid 39093952)
12. Remant Bahadur, K.C.; Bhattarai, S.R.; Aryal, S.; Khil, M.S.; Dharmaraj N.; Kim, H.Y. Novel amphiphilic triblock copolymer based on PPDO, PCL, and PEG: Synthesis, characterization, and aqueous dispersion. Colloids Surfaces A., 2007, 292(1), 69-78. (Pubitemid 44920362)
13. Wei, X.; Gong, C.; Shi, S.; Fu, S.; Men, K.; Zeng, S.; Zheng, X.; Gou, M.; Chen, L.; Qiu, L.; Qian, Z. Self-assembled honokiolloaded micelles based on poly([var epsilon]-caprolactone)- poly(ethylene glycol)-poly([var epsilon]-caprolactone) copolymer. Int. J. Pharm., 2009, 369(1-2), 170-175.
14. Connor, E.E.; Mwamuka, J.; Gole, A.; Murphy, C.J.; Wyatt, M.D. Gold nanoparticles are taken up by human cells but do not cause acute cytotoxicity. Small, 2005, 1(3), 325-327. (Pubitemid 43951781)
15. Kim, Y.P.; Oh, Y.H.; Kim, H.S. Protein kinase assay on peptideconjugated gold nanoparticles. Biosens. Bioelectron., 2008, 23(7), 980-986.
16. Lee, M.K.; Lim, S.J.; Kim, C.K. Preparation, characterization and in vitro cytotoxicity of paclitaxel-loaded sterically stabilized solid lipid nanoparticles. Biomaterials, 2007, 28(12), 2137-2146.
17. Wissing, S.A.; Kayser, O.; Müller, R.H. Solid lipid nanoparticles for parenteral drug delivery. Adv. Drug Deliv. Rev., 2004, 56(9), 1257-1272. (Pubitemid 38510473)
18. Abdelbary, G.; Fahmy, R.H. Diazepam-Loaded Solid Lipid Nanoparticles: Design and Characterization. Aaps Pharmscitech, 2009, 10(1), 211-219.
19. Müller, R.H.; Mäder, K.; Gohla, S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur. J. Pharm. Biopharm., 2000, 50(1), 161-177. (Pubitemid 30326695)
20. Fundaro, A.; Cavalli, R.; Bargoni, A.; Vighetto, D.; Zara, G.P.; Gasco, M.R. Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: Pharmacokinetics and tissue distribution after i.v. administration to rats. Pharmacol. Res., 2000, 42(4), 337-343.
21. Matsumura, Y.; Maeda, H. A New Concept for Macromolecular Therapeutics in Cancer Chemotherapy: Mechanism of Tumoritropic Accumulation of Proteins and the Antitumor Agent Smancs. Cancer Res., 1986, pp. 6387-6392. (Pubitemid 17221789)
22. Maeda, H.; Wu, J.; Sawa, T.; Matsumura, Y.; Hori, K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release, 2000, 65(1-2), 271-284. (Pubitemid 30122932)
23. Maeda, H. Soluble polymer for targeting of anticancer drugs: Basic principles and EPR effect. 23rd International Symposium on Controlled Release of Bioactive Materials, 1996 Proceedings, 1996, 167-168, 940.
24. Maeda, H.; Greish, K.; Fang, J. The EPR effect and polymeric drugs: A paradigm shift for cancer chemotherapy in the 21st century. Polymer Therapeutics Ii: Polymers as Drugs. Conjugates and Gene Delivery Systems, 2006, 193, 103-121.
25. Maeda, H.; Bharate, G.Y.; Daruwalla, J. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur. J. Pharm. Biopharm., 2009, 71(3), 409-419.
26. Maeda, H. Tumor-Selective Delivery of Macromolecular Drugs via the EPR Effect: Background and Future Prospects. Bioconjugate Chem., 2010, 21(5), 797-802.
27. Maeda, H. EPR-effect, its mechanism, and further extension towards more tumour selective cancer therapy. J. Pharm. Pharmacol., 2007, 59, A71-A72.
28. Maeda, H. The enhanced permeability and retention (EPR) effect in tumor vasculature: The key role of tumor-selective macromolecular drug targeting. Adv. Enzym. Regul., 2001, 41(1), 189-207.
29. Jain, R.K. Delivery of molecular and cellular medicine to solid tumors. Adv. Drug Deliv. Rev., 2001, 46(1-3), 149-168.
30. Heath, J.R.; Davis, M.E.; Hood, L. Nanomedicine Targets CANCER. Sci. Amer., 2009, 300(2), 44-51.
31. Torchilin, V.P. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov., 2005, 4(2), 145-160. (Pubitemid 40282557)
32. Park, J.W.; Hong, K.L.; Kirpotin, D.B.; Colbern, G.; Shalaby, R.; Baselga, J.; Shao, Y.; Nielsen, U.B.; Marks, J.D.; Moore, D.; Papahadjopoulos, D.; Benz, C.C. Anti-HER2 immunoliposomes: Enhanced efficacy attributable to targeted delivery. Clin. Cancer Res., 2002, 8(4), 1172-1181. (Pubitemid 35177372)
33. Mamot, C.; Drummond, D.C.; Noble, C.O.; Kallab, V.; Guo, Z.X.; Hong, K.L.; Kirpotin, D.B.; Park, J.W. Epidermal growth factor receptor- targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res., 2005, 65(24), 11631-11638. (Pubitemid 41821723)
34. Farokhzad, O.C.; Cheng, J.J.; Teply, B.A.; Sherifi, I.; Jon, S.; Kantoff, P.W.; Richie, J.P.; Langer, R. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc. Nat. Acad. Sci. USA., 2006, 103(16), 6315-6320.
35. Park, E.K.; Kim, S.Y.; Lee, S.B.; Lee, Y.M. Folate-conjugated methoxy poly(ethylene glycol)/poly([var epsilon]-caprolactone) amphiphilic block copolymeric micelles for tumor-targeted drug delivery. J. Control. Release, 2005, 109(1-3), 158-168. (Pubitemid 41737262)
36. Lian, J.F.; Zhang, S.Q.; Wang, J.W.; Fang, K.Q.; Zhang, Y.M.; Hao, Y. Novel galactosylated SLN for hepatocyte-selective targeting of floxuridinyl diacetate. J. Drug Target., 2008, 16(3), 250-256. (Pubitemid 351460654)
37. Brioschi, A.; Zenga, F.; Zara, G.P.; Gasco, M.R.; Ducati, A.; Mauro, A. Solid lipid nanoparticles: could they help to improve the efficacy of pharmacologic treatments for brain tumors? Neurol. Res., 2007, 29(3), 324-330. (Pubitemid 46802372)
38. Manjunath, K.; Reddy, J.S.; Venkateswarlu, V. Solid lipid nanoparticles as drug delivery systems. Methods Find. Exp. Clin. Pharmacol, 2005, 27(2), 127-144.
39. Acharya, S.; Dilnawaz, F.; Sahoo, S.K. Targeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy. Biomaterials, 2009, 30(29), 5737-5750.
40. Cirstoiu-Hapca, A.; Buchegger, F.; Lange, N.; Bossy, L.; Gurny, R.; Delie, F. Benefit of anti-HER2-coated paclitaxel-loaded immuno- nanoparticles in the treatment of disseminated ovarian cancer: Therapeutic efficacy and biodistribution in mice. J. Control. Release, 2010, 144(3), 324-331.
41. Iyer, A.K.; Khaled, G.; Fang, J.; Maeda, H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov. Today, 2006, 11(17-18), 812-818. (Pubitemid 44280021)
42. Stolnik, S.; Illum, L.; Davis, S.S. Long Circulating Microparticulate Drug Carriers. Adv. Drug Deliv. Rev., 1995, 16(2-3), 195-214.
43. Metselaar, J.M.; Bruin, P.; de Boer, L.W.T.; de Vringer, T.; Snel, C.; Oussoren, C.; Wauben, M.H.M.; Crommelin, D.J.A.; Storm, G.; Hennink, W.E. A novel family of L-amino acid-based biodegradable polymer-lipid conjugates for the development of longcirculating liposomes with effective drug-targeting capacity. Bioconjugate Chem., 2003, 14(6), 1156-1164. (Pubitemid 37449043)
44. Venturoli, D.; Rippe, B. Ficoll and dextran vs. globular proteins as probes for testing glomerular permselectivity: effects of molecular size, shape, charge, and deformability. Amer. J. Physiolo-Renal Physiol., 2005, 288(4), F605-F613. (Pubitemid 40381726)
45. Tong, R.; Cheng, J.J. Anticancer polymeric nanomedicines. Polym Rev., 2007, 47(3), 345-381. (Pubitemid 47240845)
46. Liu, J.; Lee, H.; Allen, C. Formulation of drugs in block copolymer micelles: Drug loading and release. Curr. Pharm. Design., 2006, 12(36), 4685-4701. (Pubitemid 44835137)
47. Nagayasu, A.; Uchiyama, K.; Kiwada, H. The size of liposomes: a factor which affects their targeting efficiency to tumors and therapeutic activity of liposomal antitumor drugs. Adv. Drug Deliv. Rev., 1999, 40(1-2), 75-87. (Pubitemid 29486605)
48. Schiffelers, R.M.; Bakker-Woudenberg, I.A.J.M.; Snijders, S.V.; Storm, G. Localization of sterically stabilized liposomes in Klebsiella pneumoniae-infected rat lung tissue: influence of liposome characteristics. BB A-Biomembranes, 1999, 1421(2), 329-339. (Pubitemid 29460673)
49. Agashe, H.; Lagisetty, P.; Awasthi, S.; Awasthi, V. Improved formulation of liposome-encapsulated hemoglobin with an anionic non-phospholipid. Colloid Surfaces B., 2010, 75(2), 573-583.
50. Yaroslavov, A.A.; Efimova, A.A.; Sybachin, A.V. Effect of the phase state of the lipid bilayer on the structure and characteristics of the polycation-(anionic liposome) complex. Poly. Sci. Ser. A, 2009, 51(6), 638-647.
51. Mozafari, M.R.; Reed, C.J.; Rostron, C.; Kocum, C.; Piskin, E. Construction of stable anionic liposome-plasmid particles using the heating method: A preliminary investigation. Cell Mol. Biol Lett., 2002, 7(3), 923-927. (Pubitemid 35334385)
52. Alino, S.F. Long-term expression of the human alpha 1-antitrypsin gene in mice employing anionic and cationic liposome vector. Biochem. Pharmacol., 1997, 54(1), 9-13. (Pubitemid 27353802)
53. Crespo, J.; Blaya, C.; Crespo, A.; Alino, S.F. Long-term expression of the human alpha 1-antitrypsin gene in mice employing anionic and cationic liposome vectors. Biochem Pharmacol., 1996,i(10), 1309-1314. (Pubitemid 26142856)
54. Lee, R.J.; Huang, L. Folate-targeted, anionic liposome-entrapped polylysine-condensed DNA for tumor cell-specific gene transfer. J. Biol. Chem., 1996, 271(14), 8481-8487. (Pubitemid 26108687)
55. Dinauer, N.; Balthasar, S. ; Weber, C.; Kreuter, J.; Langer, K.; von Briesen, H. Selective targeting of antibody-conjugated nanoparticles to leukemic cells and primary T-lymphocytes. Biomaterials, 2005, 26(29), 5898-5906. (Pubitemid 40803459)
56. Mastrobattista, E.; Storm, G.; van Bloois, L.; Reszka, R. . Bloemen, P.G.M.; Crommelin, D.J.A.; Henricks, P.A.J. Cellular uptake of liposomes targeted to intercellular adhesion molecule-1 (ICAM- 1) on bronchial epithelial cells. BBA-Biomembranes., 1999, 1419(2), 353-363. (Pubitemid 29322725)
57. Forssen, E.; Willis, M. Ligand-targeted liposomes. Adv. Drug Deliv. Rev., 1998, 29(3), 249-271. (Pubitemid 28090045)
58. Willis, M.C.; Collins, B.; Zhang, T.; Green, L.S.; Sebesta, D.P.; Bell, C.; Kellogg, E.; Gill, S.C.; Magallanez, A.; Knauer, S.; Bendele, R.A.; Gill, P.S.; Janjic, N. Liposome anchored vascular endothelial growth factor aptamers. Bioconjug. Chem., 1998, 9(5), 573-582.
59. Willis, M.C. ; Collins, B.D.; Zhang, T.; Green, L.S.; Sebesta, D.P.; Bell, C.; Kellogg, E.; Gill, S.C.; Magallanez, A.; Knauer, S.; Bendele, R.A.; Gill, P.S. ; Janjic. N. Liposome-anchored vascular endothelial, growth factor aptamers (vol 9, pg 573, 1998). Bioconjug. Chem., 1998, 9(5), 633-633.
60. van Rooy, I.; Cakir-Tascioglu, S.; Couraud, P.O.; Romero, I.A.; Weksler, B.; Storm, G.; Hennink, W.E.; Schiffelers, R.M.; Mastrobattista, E. Identification of Peptide Ligands for Targeting to the Blood-Brain Barrier. Pharmaceut. Res., 2010, 27(4), 673-682.
61. Danhier, F.; Vroman, B.; Lecouturier, N.; Crokart, N.; Pourcelle, V.; Freichels, H.; Jerome, C.; Marchand-Brynaert, J.; Feron, O.; Preat, V. Targeting of tumor endothelium by RGD-grafted PLGAnanoparticles loaded with Paclitaxel. J. Control. Release, 2009, 140(2), 166-173.
62. Nasongkla, N.; Bey, E. ; Ren, J.M.; Ai, H.; Khemtong, C.; Guthi, J.S.; Chin, S.F.; Sherry, A.D.; Boothman, D.A.; Gao, J.M. Multifunctional polymeric micelles as cancer-targeted, MRIultrasensitive drug delivery systems. Nano Lett., 2006, 6(11), 2427- 2430. (Pubitemid 46076928)
63. Nasongkla, N.; Shuai, X.; Ai, H.; Weinberg, B.D.; Pink, J.; Boothman, D.A.; Gao, J.M. cRGD-functionalized polymer micelles for targeted doxorubicin delivery. Angew Chem. Int. Ed., 2004, 43(46), 6323-6327. (Pubitemid 40029462)
64. Pourcelle, V.; Devouge, S.; Garinot, M.; Preat, V.; Marchand-Brynaert, J. PCL-PEG-Based nanoparticles grafted with GRGDS peptide: Preparation and surface analysis by XPS, Biomacromolecules, 2007, 8(12), 3977-3983.
65. Garinot, M.; Fievez, V.; Pourcelle,V.; Stoffelbach, F.; des Rieux, A.; Plapied, L.; Theate, I.; Freichels, H.; Jerome, C.; Marchand-Brynaert, J.; Schneider, Y.J. ; Preat, V. PEGylated PLGA-based nanoparticles targeting M cells for oral vaccination. J. Control. Release, 2007, 120(3), 195-204. (Pubitemid 47061488)
66. Yang, X.Q.; Grailer, J.J.; Pilla, S.; Steeber, D.A.; Gong, S.Q. Tumor- Targeting, pH-Responsive, and Stable Unimolecular Micelles as Drug Nanocarriers for Targeted Cancer Therapy. Bioconjugate Chem., 2010, 21(3), 496-504.
67. Daniels, T.R.; Delgado, T.; Helguera, G.; Penichet, M.L. The transferrin receptor part II: Targeted delivery of therapeutic agents into cancer cells. Clin. Immunol., 2006, 121(2), 159-176. (Pubitemid 44572972)
68. Rieger, J.; Stoffelbach, F.; Cui, D.; Imberty, A.; Lameignere, E.; Putaux,J.L.; Jerome, R.; R. Auzely-Velty, Mannosylated poly(ethylene oxide)-b-Poly(is an element of-caprolactone) dibloclk copolymers: Synthesis, characterization, and interaction with a bacterial lectin. Biomacromolecules, 2007, 8(9), 2717-2725.
69. Jeong, Y.I.; Seo, S.J.; Park, I.K.; Lee, H.C.; Kang, I.C.; Akaike, T.; Cho, C.S. Cellular recognition of paclitaxel-loaded polymeric nanoparticles composed of poly(gamma-benzul L-glutamate) and poly(ethylene glycol) diblock copolymer endcapped with galactose moiety. Int. J. Pharm., 2005, 296(1-2), 151-161. (Pubitemid 40693384)
70. Gref, R.; Couvreur, P.; Barratt, G.; Mysiakine, E. Surfaceengineered nanoparticles for multiple ligand coupling. Biomaterials, 2003, 24(24), 4529-4537. (Pubitemid 36960147)
71. Yadav, A.K.; Mishra, P.; Jain, S.; Mishra, P.; Mishra, A.K.; Agrawal, G.P. Preparation and characterization of HA-PEG-PCL intelligent core-corona nanoparticles for delivery of doxorubicin. J Drug Target., 2008, 16(6), 464-478. (Pubitemid 352015815)
72. Anabousi, S.; Kleemann, E.; Bakowsky, U.; Kissel, T.; Schmehl, T.; Gessler, T.; Seeger, W.; Lehr, C.M.; Ehrhardt, C. Effect of PEGylation on the stability of liposomes during nebulisation and in lung surfactant. J. Nanosci. Nanotechnol., 2006, 6(9-10), 3010- 3016. (Pubitemid 44579976)
73. Craparo, E.F.; Cavallaro, G.; Bondi, M.L.; Mandracchia, D.; Giammona, G. PEGylated nanoparticles based on a polyaspartamide. Preparation, physico-chemical characterization, and intracellular uptake. Biomacromolecules, 2006, 7(11), 3083-3092. (Pubitemid 46039964)
74. Immordino, M.L.; Dosio, L. F. Cattel, Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int. J. Nanomed., 2006, 1(3), 297-315.
75. Teshima, M.; Kawakami, S.; Fumoto, S.; Nishida, K.; Nakamura, J.; Nakashima, M.; Nakagawa, H.; Ichikawa, N.; Sasaki, H. PEGylated liposomes loading palmitoyl prednisolone for prolonged blood concentration of prednisolone. Biol. Pharm. Bull., 2006, 29(7), 1436-1440.
76. Xu, L.; Wang, W.; Sheng, Y.C.; Zheng, Q.S. Pharmacokinetics and its relation to toxicity of pegylated-liposomal doxorubicin in chinese patients with breast tumours. J. Clin. Pharm. Ther., 2010, 35(5), 593-601.
77. Andreopoulou, E.; Gaiotti, D.; Kim, E.; Downey, A.; Mirchandani, D.; Hamilton, A.; Jacobs, A.; Curtin, J.; Muggia, F. Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil (R)): Experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer. Ann. Oncol., 2007, 18(4), 716-721. (Pubitemid 46523276)
78. Gabizon, A.; Martin, F. Polyethylene glycol coated liposomal doxorubicin - Rationale for use in solid tumours. Drugs, 1997, 54, 15-21 (Pubitemid 27487791)
79. Lu, W.L.; Qi, X.R.; Zhang, Q.; Li, R.Y.; Wang, G.L.; Zhang, R.J.; Wei, S.L. A pegylated liposomal platform: Pharmacokinetics, pharmacodynamics, and toxicity in mice using doxorubicin as a model drug. J. Pharmacol. Sci., 2004, 95(3), 381-389. (Pubitemid 39037899)
80. Briasoulis, E.; Karavasilis, V.; Tzamakou, E.; Rammou, D.; Soulti, K.; Piperidou, C.; Pavlidis, N. Interaction pharmacokinetics of pegylated liposomal doxorubicin (Caelyx) on coadministration with paclitaxel or docetaxel. Cancer Chemother. Pharmacol., 2004, 53(5), 452-457. (Pubitemid 38553669)
81. Charrois, G.J.R.; Allen, T.M. Multiple injections of pegylated liposomal doxorubicin: Pharmacokinetics and therapeutic activity. J. Pharmacol. Exp. Ther., 2003, 306(3), 1058-1067. (Pubitemid 37025314)
82. Gabizon, A.; Shmeeda, H.; Barenholz, Y. Pharmacokinetics of pegylated liposomal doxorubicin - Review of animal and human studies. Clin. Pharmacokinet., 2003, 42(5), 419-436. (Pubitemid 36649037)
83. Gabizon, A.; Tzemach, D.; Mak, L.; Bronstein, M.; Horowitz, A.T. Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models. J. Drug Target., 2002, 10(7), 539-548. (Pubitemid 36124352)
84. Marina, N.M.; Cochrane, D.; Harney, E.; Zomorodi, K.; Blaney, S.; Winick, N.; Bernstein, M.; Link, M.P. Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: A pediatric oncology group study. Clin Cancer Res., 2002, 8(2), 413-418. (Pubitemid 34193958)
85. Lyass, O.; Uziely, B.; Ben-Yosef, R.; Tzemach, D.; Heshing, N.I.; Lotem, M.; Brufman, G.; Gabizon, A. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer, 2000, 89(5), 1037-1047.
86. Hilger, e. al., DOXIL Pharmacokinetics. Proc. Am. Soc. Clin. Oncol., 2001, 20,116a.
87. Shirakawa, M.; Yamamto, T.; Nakai, K.; Aburai, K.; Kawatobi, S.; Tsurubuchi, T.; Yamamoto, Y.; Yokoyama, Y.; Okuno, H.; Matsumura, A. Synthesis and evaluation of a novel liposome containing BPA-peptide conjugate for BNCT. Appl. Radiat. Isotopes, 2009, 67(7-8), S88-S90.
88. Yagi, N.; Yano, Y.; Hatanaka, K.; Yokoyama, Y. ; Okuno, H.; Synthesis and evaluation of a novel lipid-peptide conjugate for functionalized liposome. Bioorg. Med. Chem. Lett., 2007, 17(9), 2590-2593. (Pubitemid 46507768)
89. Song, S.X.; Liu, D.; Peng, J.L.; Sun, Y.; Li, Z.H.; Gu, J.R.; Xu, Y.H. Peptide ligand-mediated liposome distribution and targeting to EGFR expressing tumor in vivo. Int. J. Pharm., 2008, 363(1-2), 155-161.
90. Taniguchi, Y.; Kawano, K. ; Minowa, T.; Sugino, T.; Shimojo, Y.; Maitani, Y. Enhanced antitumor efficacy of folate-linked liposomal doxorubicin with TGF-beta type I receptor inhibitor. Cancer Sci., 2010, 101(10), 2207-2213.
91. Kim, S.Y.; Shin, I.G.; Lee, Y.M.; Preparation and characterization of biodegradable nanospheres composed of methoxy poly(ethylene glycol) and DL-lactide block copolymer as novel drug carriers. J. Control. Release, 1998, 56(1-3), 197-208. (Pubitemid 28511140)
92. Lee, H.; Zeng, F.Q.; Dunne, M.; Allen, C. Methoxy poly(ethylene glycol)-block-poly(delta-valerolactone) copolymer micelles for formulation of hydrophobic drugs. Biomacromolecules, 2005, 6, 3119-3128. (Pubitemid 41781531)
93. Kwon, K.W.; Park, M.J.; Bae, Y.H.; Kim, H.D.; Char, K.; Gelation behavior of PEO-PLGA-PEO triblock copolymers in water. Polymer, 2002, 43(11), 3353-3358. (Pubitemid 34292932)
94. He, G.; Ma, L.L.; Pan, J.; Venkatraman, S. ABA and BAB type triblock copolymers of PEG and PLA: A comparative study of drug release properties and "stealth" particle characteristics. Int. J. Pharm., 2007, 334(1-2), 48-55. (Pubitemid 46400312)
95. Zhang, X.W.; Zhu, X.Q.; Ke, F.Y.; Ye, L.; Chen, E.Q.; Zhang, A.Y.; Feng, Z.G. Preparation and self-assembly of amphiphilic triblock copolymers with polyrotaxane as a middle block and their application as carrier for the controlled release of Amphotericin B. Polymer, 2009, 50(18), 4343-4351.
96. Wang, Y.S.; Youngster, S.; Grace, M.; Bausch, J.; Bordens, R.; Wyss, D.F. Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications. Advan. Drug Deliv. Rev., 2002, 54(4), 547-570. (Pubitemid 34618512)
97. B. Shi, C. Fang, M.X. You, Y. Zhang, S.K. Fu, Y.Y. Pei, Stealth MePEG-PCL micelles: effects of polymer composition on micelle physicochemical characteristics, in vitro drug release, in vivo pharmacokinetics in rats and biodistribution in S-180 tumor bearing mice, Colloid Polym Sci., 2005, 283(9), 954-967.
98. A. Gopferich, R. Gref, Y. Minamitake, L. Shieh, M.J. Alonso, Y. Tabata, R. Langer, Drug-Delivery from Bioerodible Polymers - Systemic and Intravenous Administration, Formulation and Delivery of Proteins and Peptides, 1994, 567, 242-277.
99. P. Jie, S.S. Venkatraman, F. Min, B.Y.C. Freddy, G.L. Huat, Micelle- like nanoparticles of star-branched PEO-PLA copolymers as chemotherapeutic carrier, J Control Release., 2005, 110(1), 20-33.
100. Zhang, H.; Xia, H.; Wang, J.; Li, Y. High intensity focused ultrasound- responsive release behavior of PLA-b-PEG copolymer micelles. J. Control. Release, 2009, 139(1), 31-39.
101. Xiong, M.P.; Ýn̈ez, J.A.; Remsberg, C.M.; Ohgami, Y.; Kwon, G.S.; Davies, N.M.; Forrest, M.L. Formulation of a geldanamycin prodrug in mPEG-b-PCL micelles greatly enhances tolerability and pharmacokinetics in rats. J. Control. Release, 2008, 129(1), 33-40.
102. Jette, K.K.; Law, D.; Schmitt, E.A.; Kwon, G.S. Preparation and drug loading of poly(ethylene glycol)-block-poly(epsiloncaprolactone) micelles through the evaporation of a cosolvent azeotrope. Pharmaceut. Res., 2004, 21(7), 1184-1191. (Pubitemid 38954202)
103. Lee, J.S.; Bae, J.W.; Joung, Y.K.; Lee, S.J.; Han, D.K.; Park, K.D. Controlled dual release of basic fibroblast growth factor and indomethacin from heparin-conjugated polymeric micelle. Int. J. Pharm., 2008, 346(1-2), 57-63. (Pubitemid 350110508)
104. Jin, C.; Qian, N.S.; Zhao, W.; Yang, W.Q.; Bai, L.; Wu, H.; Wang, M.C.; Song, W.J.; Dou, K.F. Improved Therapeutic Effect of DOX-PLGA-PEG Micelles Decorated with Bivalent Fragment HAb18 F(ab ')(2) for Hepatocellular Carcinoma. Biomacromolecules, 2010, 11(9), 2422-2431.
105. Yoo, H.S.; Park, T.G. Biodegradable polymeric micelles composed of doxorubicin conjugated PLGA-PEG block copolymer. J. Control. Release, 2001, 70(1-2), 63-70. (Pubitemid 32144793)
106. Kim, J.; Shin, S. Cost-Effectiveness of Genexol-PM for Treating Metastatic Breast Cancer. J. Breast Cancer, 2010, 13(1), 104-110.
107. Lim, W.T.; Tan, E.H.; Toh, C.K.; Hee, S.W.; Leong, S.S.; Ang, P.C.S.; Wong, N.S. ; Chowbay, B. Phase I pharmacokinetic study of a weekly liposomal paclitaxel formulation (Genexol (R)-PM) in patients with solid tumors. Ann Oncol., 2010, 21(2), 382-388.
108. Lee, K.S.; Chung, H.C.; Im, S.A.; Park, Y.H.; Kim, C.S.; Kim, S.B.; Rha, S.Y.; Lee, M.Y.; Ro, J. Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Res Treat., 2008, 108(2), 241-250. (Pubitemid 351311357)
109. Kim, D.W.; Kim, S.Y.; Kim, H.K.; Kim, S.W.; Shin, S.W.; Kim, J.S.; Park, K.; Lee, M.Y.; Heo, D.S. Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced nonsmall- cell lung cancer. Ann. Oncol., 2007, 18(12), 2009-2014. (Pubitemid 350286241)
110. Kim, T.Y.; Kim, D.W.; Chung, J.Y.; Shin, S.G.; Kim, S.C.; Heo, D.S.; Kim, N.K. ; Bang, Y.J. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin. Cancer Res., 2004, 10(11), 3708-3716. (Pubitemid 38697604)
111. Kim, S.C.; Kim, D.W.; Shim, Y.H.; Bang, J.S.; Oh, H.S.; Kim, S.W.; Seo, M.H. In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. J. Control. Release, 2001, 72(1- 3), 191-202. (Pubitemid 32522357)
112. Lim, W.T.; Leong, S.S.; Toh, C.K.; Ang, C.S.; Wong, N.S.; Tan, E.H.; Chowbay, B. A phase I pharmacokinetic study of a liposomal formulation of paclitaxel administered weekly to Asian patients with solid malignancies. J. Clin Oncol., 2009, 27(15), -.
113. Campos, S.M.; Matulonis, U.A.; Penson, R.T.; Lee, H.; Berkowitz, R.S.; Duska, L.R.; Fuller, A.F.; Wilson, K.S.; Puchalski, T.A.; Supko, J.G.; Seiden, M.V. Phase II study of liposomal doxorubicin and weekly paclitaxel for recurrent Mullerian tumors. Gynecol. Oncol., 2003, 90(3), 610-618.
114. H.Z. Zhao, L.Y.L. Yung, Selectivity of folate conjugated polymer micelles against different tumor cells, Int J Pharm., 2008, 349(1-2), 256-268.
115. H. Zhao, L.Y.L. Yung, Selectivity of folate conjugated polymer micelles against different tumor cells, Int J Pharm., 2008, 349(1-2), 256-268. (Pubitemid 350299702)
116. X. Han, J. Liu, M. Liu, C. Xie, C. Zhan, B. Gu, Y. Liu, L. Feng, W. Lu, 9-NC-loaded folate-conjugated polymer micelles as tumor targeted drug delivery system: Preparation and evaluation in vitro, Int J Pharm., 2009, 372(1-2), 125-131.
117. Lu, Y.J.; Sega, E.; Leamon, C.P.; Low, P.S. Folate receptortargeted immunotherapy of cancer: mechanism and therapeutic potential. Adv. Drug Deliver. Rev., 2004, 56(8), 1161-1176. (Pubitemid 38496513)
118. Choi, H.; Choi, S.R.; Zhou, R.; Kung, H.F.; Chen, I.W. Iron oxide nanoparticles as magnetic resonance contrast agent for tumor imaging via folate receptor-targeted delivery. Acad. Radiol., 2004, 11(9), 996-1004. (Pubitemid 39220809)
119. Hong, G.B.; Yuan,R.X.; Liang, B.L.; Shen, J.; Yang, X.Q.; Shuai, X.T. Folate functionalized polymeric micelle as hepatic carcinoma- targeted, MRI-ultrasensitive delivery system of antitumor drugs. Biomed. Microdevices., 2008, 10(5), 693-700.
120. Pinto Reis, C.; Neufeld, R.J.; Ribeiro, A.J.; Veiga, F. Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles. Nanomedicine: Nanotechnology, Biology and Medicine, 2006, 2(1), 8-21.
121. Dyson, P.J.; Sava, G. Metal-based antitumour drugs in the post genomic era. Dalton Trans., 2006, 16, 1929-1933. (Pubitemid 43797525)
122. Huxford, R.C.; Della Rocca, J.; Lin, W.B. Metal-organic frameworks as potential drug carriers. Curr. Opin. Chem. Biol., 2010, 14(2), 262-268.
123. Mundargi, R.C.; Babu, V.R.; Rangaswamy, V.; Patel, P.; Aminabhavi. T.M. Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives. J. Control. Release, 2008, 125(3), 193-209.
124. Mu, L.; Feng, S.S. A novel controlled release formulation for the anticancer drug paclitaxel (Taxol (R)): PLGA nanoparticles containing vitamin E TPGS. J. Control. Release, 2003, 86(1), 33-48. (Pubitemid 35469120)
125. Leo, E.; Brina, B.; Forni, F.; Vandelli, M.A. In vitro evaluation of PLA nanoparticles containing a lipophilic rug in water-soluble or insoluble form. Int. J. Pharm., 2004, 278(1), 133-141. (Pubitemid 38670444)
126. Kim, S.Y.; Lee, Y.M. Taxol-loaded block copolymer nanospheres composed of methoxy poly(ethylene glycol) and poly([var epsi lon]-caprolactone) as novel anticancer drug carriers. Biomaterials, 2001, 22(13), 1697-1704. (Pubitemid 32564958)
127. Tiyaboonchai, W.; Limpeanchob, N. Formulation and characterization of amphotericin B-chitosan-dextran sulfate nanoparticles. Int. J. Pharm., 2007, 329(1-2), 142-149. (Pubitemid 44937518)
128. Waree, T. Chitosan Nanoparticles : A Promising System for Drug Delivery. Naresuan Univ. J., 2003, 11(3), 51-56.
129. Danhier, F.; Lecouturier, N.; Vroman, B.; Jerome, C, Marchand.- Brynaert, J.; Feron, O.; Preat, V. Paclitaxel-loaded PEGylated PLGA-based nanoparticles: In vitro and in vivo evaluation. J. Control Release, 2009, 133(1), 11-17.
130. Fonseca, C.; Simoes, S.; Gaspar, R. Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity. J. Control Release, 2002, 83(2), 273- 286. (Pubitemid 35282471)
131. Wang, Z.; Liu, W.; Xu, H.; Yang, X. Preparation and in vitro Studies of Stealth PEGylated PLGA Nanoparticles as Carriers for Arsenic Trioxide. Chinese J. Chem. Eng., 2007, 15(6), 795-801.
132. Park, J.; Fong, P.M.; Lu, J.; Russell, K.S.; Booth, C.J.; Saltzman, W.M.; Fahmy, T.M. PEGylated PLGA nanoparticles for the improved delivery of doxorubicin. Nanomedicine: Nanotechnology. Biology and Medicine, 2009, 5(4), 410-418.
133. Fonseca, C.; Simoes, S.; Gaspar, R. Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity. J. Control Release, 2002, 83(2), 273- 286. (Pubitemid 35282471)
134. Yadav, A.K.; Mishra, P.; Mishra, A.K.; Mishra, P.; Jain, S.; Agrawal, G.P. Development and characterization of hyaluronic acid-anchored PLGA nanoparticulate carriers of doxorubicin. Nanomedicine: Nanotechnology. Biology and Medicine, 2007, 3(4), 246-257. (Pubitemid 350199644)
135. Betancourt, T.; Brown, B.; Brannon-Peppas, L. Doxorubicinloaded PLGA nanoparticles by nanoprecipitation: preparation, characterization and in vitro evaluation. Nanomedicine, 2007, 2(2), 219-232. (Pubitemid 46845768)
136. Sastre, R.L.; Olmo, R.; Teijon, C.; Muniz, E.; Teijon, E.J.M.; Blanco, J.; Blanco, M.D. 5-Fluorouracil plasma levels and biodegradation of subcutaneously injected drug-loaded microspheres prepared by spray-drying poly(d,l-lactide) and poly(d,l-lactide-coglycolide) polymers. Int. J. Pharm., 2007, 338(1-2), 180-190. (Pubitemid 46777237)
137. Hitzman, C.J.; Elmquist, W.F.; Wattenberg, L.W.; Wiedmann, T.S. Development of a respirable, sustained release microcarrier for 5- fluorouracil I: In vitro assessment of liposomes, microspheres, and lipid coated nanoparticles. J. Pharm. Sci., 2006, 95(5), 1114-1126. (Pubitemid 43723169)
138. Sastre, R.L.; Olmo, R.; Teijon, C.; Muniz, E.; Teijon, J.M.; Blanco, M.D. 5-Fluorouracil plasma levels and biodegradation of subcutaneously injected drug-loaded microspheres prepared by spraydrying poly(D,L-lactide) and poly(D,L-lactide-co-glycolide) polymers. Int. J. Pharm., 2007, 338(1-2), 180-190. (Pubitemid 46777237)
139. Derakhshandeh, K.; Erfan, M.; Dadashzadeh, S. Encapsulation of 9-nitrocamptothecin, a novel anticancer drug, in biodegradable nanoparticles: Factorial design, characterization and release kinetics. Eur.J. Pharm. Biopharm., 2007, 66(1), 34-41. (Pubitemid 46412968)
140. Mattheolabakis, G.; Taoufik, E.; Haralambous, S.; Roberts, M.L.; Avgoustakis, K.; In vivo investigation of tolerance and antitumor activity of cisplatin-loaded PLGA-mPEG nanoparticles. Eur. J. Pharm. Biopharm., 2009, 71(2), 190-195.
141. Beletsi, A.; Klepetsanis, P.; Ithakissios, D.S.; Kounias, S.; Stavropoulos, A.; Avgoustakis, K. Simultaneous optimization of cisplatin- loaded PLGA-mPEG nanoparticles with regard to their size and drug encapsulation. Curr. Nanosci., 2008, 4(2), 173-178. (Pubitemid 352024788)
142. Gryparis, E.C.; Mattheolabakis, G.; Bikiaris, D.; Avgoustakis, K. Effect of conditions of preparation on the size and encapsulation properties of PLGA-mPEG nanoparticles of cisplatin, Drug Deliv., 2007, 15(6), 371-380. (Pubitemid 47265821)
143. Gryparis, E.C.; Hatziapostolou, M.; Papadimitriou, E.; Avgoustakis, K. Anticancer activity of cisplatin-loaded PLGAmPEG nanoparticles on LNCaP prostate cancer cells. Eur. J. Pharm. Biopharm., 2007, 67(1), 1-8. (Pubitemid 46991325)
144. Avgoustakis, K.; Beletsi, A.; Panagi, Z.; Klepetsanis, P.; Karydas, A.G.; Ithakissios, D.S. PLGA-mPEG nanoparticles of cisplatin: in vitro nanoparticle degradation, in vitro drug release and in Vivo drug residence in blood properties. J. Control Release, 2002, 79(1- 3), 123-135. (Pubitemid 34164166)
145. Di Toro, R.; Betti, V.; Spampinato, S. Biocompatibility and integrin- mediated adhesion of human osteoblasts to poly(DL-lactideco- glycolide) copolymers. Eur. J. Pharm Sci., 2004, 21(2-3), 161- 169. (Pubitemid 38156153)
146. Michalak, G.J.; Goodrich, G.P.; Schwartz, J.A.; James, W.D.; O'Neal, D.P. Murine photoplethysmography for in vivo estimation of vascular gold nanoshell concentration, J. Biomed. Opt., 2010, 15(4), 047007.
147. Hubenthal, F.; Borg, N.; Trager, F. Optical properties and ultrafast electron dynamics in gold-silver alloy and core-shell nanoparticles. Appl. Phys. B-Lasers Opt., 2008, 93(1), 39-45.
148. Zhu, J.; Wang, Y.C. Simulation of the medium dielectric constant dependent optical properties for gold nanorods. Spectros. Spectr. Anal., 2005, 25(6), 916-919. (Pubitemid 40918295)
149. Averitt, R.D.; Westcott, S.L.; Halas, N.J. Linear optical properties of gold nanoshells. J. Opt. Soc. Am. B-Opt Physics, 1999, 16(10), 1824-1832. (Pubitemid 129655820)
150. Cengelli, F.; Voinesco, F.; Juillerat-Jeanneret, L. Interaction of cationic ultrasmall superparamagnetic iron oxide nanoparticles with human melanoma cells. Nanomedicine, 2010, 5(7), 1075-1087.
151. Yoo, M.K.; Park, I.Y.; Kim, I.Y.; Park, I.K.; Kwon, J.S.; Jeong, H.J.; Jeong, Y.Y.; Cho, C.S. Superparamagnetic Iron Oxide Nanoparticles Coated with Mannan for Macrophage Targeting. J. Nanosci Nanotechnol., 2008, 8(10), 5196-5202.
152. Yu, M.K.; Jeong, Y.Y.; Park, J.; Park, S.; Kim, J.W.; Min, J.J.; Kim, K.; Jon, S. Drug-loaded superparamagnetic iron oxide nanoparticles for combined cancer imaging and therapy in vivo. Angew Chem. Int. Ed., 2008, 47(29), 5362-5365.
153. Petri-Fink, A.; Hofmann, H. Superparamagnetic iron oxide nanoparticles (SPIONs): From synthesis to in vivo studies - A summary of the synthesis, characterization, in vitro, and in vivo investigations of SPIONs with particular focus on surface and colloidal properties. Ieee T. Nanobiosci., 2007, 6(4), 289-297. (Pubitemid 350210542)
154. Xu, Z.P.; Zeng, Q.H.; Lu, G.Q.; Yu, A.B. Inorganic nanoparticles as carriers for efficient cellular delivery. Chem. Eng. Sci., 2006, 61(3), 1027-1040. (Pubitemid 41650188)
155. Myllynen, P.K.; Loughran, M.J.; Howard, C.V.; Sormunen, R.; Walsh, A.A.; Vahakangas, K.H. Kinetics of gold nanoparticles in the human placenta. Reprod. Toxicol., 2008, 26(2), 130-137.
156. Gradishar, W.J.; Tjulandin, S.; Davidson, N.; Shaw, H.; Desai, N.; Bhar, P.; Hawkins, M.; O'Shaughnessy, J. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J. Clin. Oncol., 2005, 23(31), 7794-7803. (Pubitemid 46657376)
157. Muller, R.H.; Mader, K.; Gohla, S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur. J. Pharm. Biopharm., 2000, 50(1), 161-177. (Pubitemid 30326695)
158. Muller, R.H.; Mehnert, W.; Lucks, J.S.; Schwarz, C.; Zurmuhlen, A.; Weyhers, H.; Freitas, C.; Ruhl, D. Solid Lipid Nanoparticles (Sln) - an Alternative Colloidal Carrier System for Controlled Drug-Delivery. Eur. J. Pharma. Biopharm., 1995, 41(1), 62-69.
159. Lander, R.; Manger, W.; Scouloudis, M.; Ku, A.; Davis, C.; Lee, A. Gaulin homogenization: A mechanistic study. Biotechnol. Progr., 2000, 16(1), 80-85. (Pubitemid 30097655)
160. Lippacher, A.; Muller, R.H.; Mader, K. Semisolid SLN (TM) dispersions for topical application: influence of formulation and production parameters on viscoelastic properties. Eur. J. Pharm Biopharm., 2002, 53(2), 155-160. (Pubitemid 34189788)
161. Jenning, V. A. Lippacher, S.H. Gohla, Medium scale production of solid lipid nanoparticles (SLN) by high pressure homogenization. J. Microencapsul., 2002, 19(1), 1-10.
162. Bilensoy, E. Nanoparticulate Delivery Systems Based on Amphiphilic Cyclodextrins. J. Biomed. Nanotechnol., 2008, 4(3), 293- 303.
163. Tagne, J.B.; Kakumanu, S.; Ortiz, D.; Shea, T.; Nicolosi, R.J. A nanoemulsion formulation of tamoxifen increases its efficacy in a breast cancer cell line. Mol. Pharm., 2008, 5(2), 280-286. (Pubitemid 351579131)
164. Dekel, Y.; Glucksam, Y.; Margalit, R. Novel fibrillar insulin formulations for oral administration: Formulation and in vivo studies in diabetic mice. J. Control Release, 2010, 143(1), 128-135.
165. Gershkovich, P.; Wasan, E.K.; Lin, M.; Sivak, O.; Leon, C.G.; Clement, J.G.; Wasan, K.M. Pharmacokinetics and biodistribution of amphotericin B in rats following oral administration in a novel lipid-based formulation (vol 64, pg 101, 2009), J. Antimicrob Chemother., 2010, 65(3), 599-599.
166. S.A. Veltkamp, B. Thijssen, J.S. Garrigue, G. Lambert, F. Lallemand, F. Binlich, A.D.R. Huitema, B. Nuijen, A. Nol, J.H. Beijnen, J.H.M. Schellens, A novel self-microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer, Br. J. Cancer, 2006, 95(6), 729-734. (Pubitemid 44373489)
167. Lippacher, A.; Muller, R.H.; Mader, K. Preparation of semisolid drug carriers for topical application based on solid lipid nanoparticles. Int. J. Pharm., 2001, 214(1-2), 9-12. (Pubitemid 32244069)
168. Xiang, Q.Y.; Wang, M.T.; Chen, F.; Gong, T.; Jian, Y.L.; Zhang, Z.R.; Huang, Y. Lung-targeting delivery of dexamethasone acetate loaded solid lipid nanoparticles. Arch. Pharm. Research, 2007, 30(4), 519-525.
169. Huang,G.H.; Zhang, N.; Bi, X.L.; Dou, M.J. Solid lipid nanoparticles of temozolomide: Potential reduction of cardial and nephric toxicity, Int. J. Pharm., 2008, 355(1-2), 314-320.
170. W. Yang, W. Wei, In situ evading of phagocytic uptake of stealth solid lipid nanoparticles by mouse peritoneal macrophages, Drug Deliv, 2006(3), 13, 189-192.
171. C. Bocca, O. Caputo, R.B. Cavalli, L. Gabriel, A. Miglietta, M.R. Gasco, Phagocytic uptake of fluorescent stealth and non-stealth solid lipid nanoparticles, Int. J. Pharm., 1998, 175(2), 185-193. (Pubitemid 28517974)
172. Liu, J.; Gong, T.; Wang, C.G.; Zhong, Z.R.; Zhang, Z.R.; Solid lipid nanoparticles loaded with insulin by sodium cholatephosphatidylcholine- based mixed micelles: Preparation and characterization. Int J. Pharm., 2007, 340(1-2), 153-162. (Pubitemid 47044961)
173. Manjunath, K.; Venkateswarlu, V. Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. J. Control Release, 2005, 107(2), 215-228. (Pubitemid 41319672)